PLEASANT PRAIRIE — Stateline 94 Corporate Park, a new corporate park under development in Pleasant Prairie, is moving closer to reality, as is its first tenant, a pharmaceutical firm.
The village Plan Commission this week approved maps and a memorandum of understanding for the first phase of public improvements for the $20 million corporate park, planned along the east frontage road between 110th and 122nd Streets — south and east of Pleasant Prairie Premium Outlets.
The first phase of the corporate park project includes installation of sewers and water mains as well as road improvements.
The corporate park is in a tax incremental financing district the Village Board approved a year ago to facilitate the improvements.
Also approved and revisited were preliminary site and operation plans for the park’s first tenant, a flagship distribution center for Fresenius Kabi.
The company is planning an order processing, assembly and fulfillment center in the 125-acre Stateline 94 Corporate Park. The 590,595-square-foot center, located on a 46.9 acre parcel, is being developed by Venture One Real Estate and CRG, a private real estate development firm of Clayco, a construction and engineering company.
Fresenius Kabi, with U.S. headquarters in Lake Zurich, Ill., specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to care for critically and chronically ill patients.
The company is closing its distribution center in Bensenville, Ill., and moving the operations to Pleasant Prairie. The facility is expected to begin operations next year with about 100 workers on two shifts. According to the application submitted to the village, the company would employ 164 workers by 2028.
Zoning for the Fresenius site dictates that the facility be used primarily for production and manufacturing; no more than 30 percent of the building can be used for storage and distribution.
At a March meeting, the commission was assured that the facility conformed with the zoning, but Plan Commission member Mike Pollocoff noted that Fresenius sent a correction that identified it as a distribution center.
“I’d like to know how you guys view this use,” he said. “I don’t want to be in a situation where we’re walking something back after we said yeah. I think based on the early representations from the developer, (it was) an assembly activity.”
Brian Kunz, supply chain management senior director for Fresenius, said there would be some assembly involved.
He said the company brings in products from different areas. They then go through specific processes, from label checking to quality control, “to ensure the accuracy and safety to our patients.”
Kunz assured Pollocoff the facility is not a repackaging facility, saying the products go to wholesalers and hospitals.
He said that while the facility was not licensed as a “repackager” there have been situations in which products had to be reprocessed under pharmaceutical protocol in which additional labeling or materials, such as a needle, had to be added.